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 2009 EMBO Molecular MedicineNon-coding microRNAs (miRs) are a vital component of post-transcriptional
modulation of protein expression and, like coding mRNAs harbour oncogenic
properties. However, the mechanisms governing miR expression and the identity
of the affected transcripts remain poorly understood. Here we identify the inositol
phosphatase SHIP1 as a bonafide target of the oncogenic miR-155. We demon-
strate that in diffuse large B cell lymphoma (DLBCL) elevated levels of miR-155,
and consequent diminished SHIP1 expression are the result of autocrine stimu-
lation by the pro-inflammatory cytokine tumour necrosis factor a (TNFa). Anti-
TNFa regimen such as eternacept or infliximab were sufficient to reducemiR-155
levels and restored SHIP1 expression in DLBCL cells with an accompanying
reduction in cell proliferation. Furthermore, we observed a substantial decrease
in tumour burden in DLBCL xenografts in response to eternacept. These findings
strongly support the concept that cytokine-regulated miRs can function as a
crucial link between inflammation and cancer, and illustrate the feasibility of
anti-TNFa therapy as a novel and immediately accessible (co)treatment for
DLBCL.INTRODUCTIONB cell survival and fate determination are strongly dependent
upon phosphatidylinositol 3-kinase (PI3K) signalling (Alizadeh
et al, 2000; Fruman, 2004). PI3K catalyses the conversion of
membrane phosphatidylinositol-(4,5)-bisphosphate to phos-
phatidylinositol-(3,4,5)-trisphosphate (PIP3), which acts as a
second messenger to recruit pleckstrin-homology domain
containing adapters and kinases such as 3’-phosphoinositide-
dependent kinase (PDK), AKT, phospholipase C g2 (PLCg2),
Bruton’s tyrosine kinase (BTK), downstream of kinase (DOK)
and others. Subsequent activation/inactivation of additional
effectors including serum and glucocorticoid-inducible kinaseciences, University of
, USA.
ospital, Copenhagen,
ospital, Copenhagen,
iego, La Jolla, CA, USA.
1 858 8221106;(SGK), target of rapamycin (TOR), protein phosphatase 2A
(PP2A), forkhead box O (FoxO) and Cyclin D/E mediates diverse
biological responses such as survival, proliferation, migration,
adhesion and differentiation. PI3K signals are antagonized by
two lipid phosphatases: the 30-inositol phosphatase (PTEN) and
the 50-inositol phosphatase (SHIP). It was recently discovered
that in contrast to T cells, B cells do not undergo malignant
transformation upon PTEN deletion (AV Miletic, A Mills, D
Mills, IM Pedersen, H Morse, J Ravetch, S Bolland, RC Rickert,
unpublished work). Similarly, deletion of SHIP1 in B cells is
insufficient to generate B cell lymphoma. However, concomitant
ablation of both SHIP1 and PTEN in murine B cells induces lethal
lymphoma resembling DLBCL with 100% penetrance, revealing
a novel role for SHIP1 as a tumour-suppressor (Miletic et al,
unpublished work).
Disease in B cell non-Hodgkin lymphoma (B-NHL) patients is
graded according to the International Prognostic Index (IPI),
which (among other things) assigns low scores for the
involvement of single lymph nodes, intermediate scores for
progression to multiple lymph node involvement and high
scores for systemic nodal and non-lymphoid metastases.EMBO Mol Med 1, 288–295 www.embomolmed.org
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human patients has suggested that B-NHL, in addition to
multiple cancer-promoting genetic ‘hits’, is fuelled by non-
specific stimuli such as B cell antigen receptor (BCR)-mediated
recognition of undefined self-antigens or soluble survival
factors. In support of this latter idea, B-NHL tumours often
display several hallmarks of antigen-mediated clonal selection
or cytokine dependence. DLBCL is clinically, morphologically
and genetically a heterogeneous group of malignant prolifera-
tion of large lymphoid B cells that accounts for approximately
40% (25,000 cases/year) of adult NHLs (Coiffier, 2001).
Standard chemotherapy has been recently expanded from
CHOP (Cyclophosphamide/Doxorubicin/Vincristine/Predniso-
lone) to R-CHOP with the inclusion of Rituximab, an anti-CD20
monoclonal antibody, which improved treatment success to an
overall 3-year relapse free survival of DLBCL patients at 53–
63.1% (Habermann et al, 2006; Pfreundschuh et al, 2008). Two
prognostically different subgroups of DLBCL have been
identified with distinct gene expression profiles either char-
acteristic of normal germinal centre (GC) B cells or of activated
memory B cells. The GC B-cell-like subgroup was correlated
with a significantly better prognosis (5-year survival: 76%) in
comparison to the activated B cell-like (ABC or non-GC)
subgroup (5-year survival: 16%) (Alizadeh et al, 2000; Shipp
et al, 2002). Furthermore, previous work by Rai et al and a very
recent report published during the preparation of this manu-
script revealed unique miR signatures for the two classes of
DLBCL (Malumbres et al, 2009; Rai et al, 2008).
In the present study we show elevated miR-155 levels and
concomitant suppression of SHIP1 expression in non-GC
compared to the GC-DLBCL cell lines or primary tumour samples.
Furthermore, we demonstrate that augmented miR-155 expres-
sion in DLBCL is a consequence of increased TNFa production
rather than genomic mutation, and can therefore be reversed in
vitro and in vivo through neutralization of TNFa, with subsequent
inhibition of cell proliferation and tumour growth.RESULTS
To determine whether a correlation exists between survival of
patients with B cell malignancies and expression levels of PTEN
and SHIP, we utilized ONCOMINE to query published cDNA
array results. Analysis of data originating from gene expression
studies by Alizadeh and Rosenwald (Alizadeh et al, 2000;
Rosenwald et al, 2002) revealed that SHIP1 levels are
significantly decreased in DLBCL compared to more indolent
chronic lymphocytic leukaemia (CLL) or follicular lymphoma
(FL) (Fig 1A). Strikingly, SHIP1 levels within the non-GC subset
displayed strong correlation with overall survival (Fig 1B)
suggesting that SHIP1 expression levels are useful prognostic
indicators of survival among DLBCL patients.
In order to determine the molecular mechanisms that mediate
the observed decrease in SHIP1 expression in DLBCL, we
determined the methylation status of the SHIP1 promoter in 44
non-GC and GC-DLBCL specimens, as well as screened for
mutations in the coding regions and splice sequences, but didwww.embomolmed.org EMBO Mol Med 1, 288–295not detect any differences among the samples (not shown).
We next considered the possibility that post-transcriptional
regulatory events mediated by small non-coding RNAs
might alter the expression of SHIP1 in these haematopoietic
malignancies. Indeed, in addition to differential expression
of coding genes, non-GC-type lymphoma cells express elevated
levels of several miRs. Scanning of the SHIP1 30-untranslated
region (30-UTR) revealed perfect sequence complementarity
with the seed sequence of miR-155 (Fig 1C), an onco-miR
whose ectopic expression gives rise to B cell malignancies
(Costinean et al, 2006), but whose cellular targets have
remained elusive.
Using a prototypic cell line model of the GC- and a non-GC-
subtypes of DLBCL, Lawrie et al showed that in addition to miR-
155, miR-221 and miR-21 were also over-expressed in non-GC-
type but not GC-type lymphoma cells (Lawrie et al, 2007). To
determine miR-155 and SHIP-mRNA levels in primary DLBCL
patient samples without concern of potential contamination by
non-malignant tissue, we isolated tumour cells by laser-capture-
microdissection (LCD) from frozen lymph node biopsies. As
shown in Fig 1D, miR-155 expression was significantly higher in
non-GC-DLBCL compared to GC-DLBCL, whereas SHIP1 mRNA
levels were lower in non-GC-DLBCL, consistent with the notion
of attenuation of SHIP1 expression by miR-155.
To establish a link between miR-155 and SHIP1 expression
beyond mere correlation, the non-GC-DLBCL cell line OCILY-3
was transfected either with a non-specific control-miR, miR-1 or
miR-155. Neither miR-1 nor the control miR affected SHIP1
mRNA levels, whereas introduction of miR-155 resulted in a
clear decrease in SHIP1 mRNA (Fig 2A). More importantly,
neutralization of endogenous miR-155 by means of a synthetic
anti-miR resulted in a dramatic increase in SHIP1 mRNA
compared to a transfection of a non-specific anti-miR control
(Fig 2A). As anticipated, the modulation of SHIP1 mRNA levels
by miR-155 or anti-miR-155 is reflected by accompanying
changes in SHIP1 protein expression (Fig 2B, left panel), and is
not unique to OCILY-3 cells, but is also observed in the OCILY-10
and Toledo cells, a widely used cell line model representative of
non-GC-DLBCL (Fig 2B, middle and right panel). In contrast,
miR-155 did not alter the expression of hSHIP2 protein (Fig S1 of
Supporting Information).
Lastly, analysing SHIP1 protein levels in B-cells isolated from
WT and miR-155 transgenic (tg) mice, we found that SHIP1 is
greatly reduced in miR-155 (tg) B-cells as compared to their WT
counterparts (not shown), further supporting the notion that
miR-155 post-transcriptionally regulates SHIP1 expression.
To investigate whether miR-155 targets and represses SHIP1
directly through 30-UTR interaction, we inserted the 30-UTR of
hSHIP1 into a reporter plasmid at the 30 end of luciferase mRNA
driven by a CMV promoter (WT 30-UTR-luc) and analysed the
effect of miR-155 on luciferase expression. As anticipated, co-
transfection of miR-155 attenuated expression of luciferase from
the WT 30-UTR-luc reporter (Fig 2C, bars 1 and 3), whereas no
inhibition was observed when a control miR (miR-CTL) was
used (Fig 2C, bar 2). Similarly, a mutated miR-155 (miR-
155mut) whose seed sequence had been altered, failed to
suppress the luciferase activity originating from WT 30-UTR-luc 2009 EMBO Molecular Medicine 289
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Figure 1. Differential SHIP1 expression correlates with prognosis of DLBCL.
A. Two independent cDNA arrays (Alizadeh (Alizadeh et al, 2000) and Rosenwald (Rosenwald et al, 2002)) were analysed in Oncomine (www.oncomine.org) for
expression of SHIP1 in DLBCL, CLL and FL. Y-axis represents normalized expression values (mean standard deviation; p-values are derived from Student’s
t-test).
B. Kaplan–Meier plots (Oncomine; Rosenwald et al, 2002) showing overall survival of 72 non-GC-DLBCL patients using defined cut-off values for SHIP1 expression
(patient sub-groups defined as having the lowest 50% (50% low: 34 patients), lowest 25% (25% low: 18 patients) or lowest 10% (10% low: 7 patients) relative
SHIP1 expression).
C. Sequence alignment of the SHIP1 30-UTR and miR-155 (TargetScan; seed sequence is highlighted in grey).
D. Frozen lymph node sections of ABC (non-GC) and GC-DLBCL patients were stained with H&E, and tumour cells (>1,000 cells/specimen) were isolated by LCD.
RNA was analysed for miR-155, SHIP1, U6 and GAPDH expression. Data represent 5 (GC) and 6 (non-GC) specimens, respectively (Wilcoxon rank sum test;
p-value miR-155: 0.08225; p-value SHIP1: 0.08125).
290plasmid (Fig 2C, bar 4). To further demonstrate the specificity
of this interaction, we also generated a luciferase reporter in
which the hSHIP1 30-UTR was modified to be complementary to
the seed sequence of miR-155mut (Mut 30-UTR-luc). This
reporter system was resistant to the inhibitory effects of miR-155
(Fig 2C, bar 7), but was repressed by miR-155mut (Fig 2C,
bar 8). These results demonstrate that miR-155 inhibits SHIP1
expression by directly interacting with the hSHIP1 30-UTR.
miR-155 is one of only a few miRs whose expression has been
shown to be regulated by extra-cellular ligands. O’Connell et al
demonstrated that miR-155 expression can be induced in
macrophages by stimulation with lipopolysaccharide (LPS) or
TNFa (O’Connell et al, 2007), and analysis of the activation
pathway indicated that miR-155 is an AP1-responsive transcript
involving the JNK pathway. B cells not only produce TNFa 2009 EMBO Molecular Medicine(Endres et al, 1999; Pasparakis et al, 1996), but they upregulate
miR-155 in response to this cytokine in a JNK-dependent
manner similar to macrophages (Fig S2 of Supporting Informa-
tion). As previous studies showed that patients with non-GC-
DLBCL display elevated serum TNFa levels compared to those
suffering from GC-DLBCL or other B cell malignancies (Pedersen
et al, 2005), the possibility that non-GC-DLBCL cells create an
auto-stimulatory loop leading to elevated miR-155 levels by
producing TNFa appeared intriguing.
To test this hypothesis, three non-GC-DLBCL cell lines
(OCILY-3, OCILY-10, Toledo) were cultured in the presence of
eternacept (Enbrel1), an antagonistic soluble TNFa receptor
that finds widespread clinical use in the treatment of
inflammatory diseases such as rheumatoid arthritis and Crohn’s
disease. Strikingly, this anti-TNFa regimen led to a substantialEMBO Mol Med 1, 288–295 www.embomolmed.org
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Figure 2. miR-155 attenuates SHIP1 expression.Non-GC-DLBCL cell lines OCILY-3, OLILY-10 and Toledo were transfected with 50mMof either non-specific miR
(miR-CTL), miR-1, miR-155, non-specific anti-miR (amiR-CTL) or anti-miR-155 (amiR-155).
A. Cells were harvested 12h post transfection, SHIP1 mRNA levels were determined by qPCR and normalized to GAPDH (mean SD; n¼4).
B. Same as (A), except cells were lysed after 72 h, and Western blot analysis was performed using antibodies against human SHIP1 and GAPDH.
C. Luciferase constructs containing either the wild-type (WT) or mutated (Mut) hSHIP1 30UTR (50 ng) and the indicatedmiRs (1 nM;miR-CTL, miR-155 ormutated
miR-155 (miR-155mut)) were transfected into 293T cells, and luciferase activity was determined 24 h post transfection. Graph indicates relative luciferase
values after normalization to co-transfected renilla luciferase (mean SD, n¼5, p-values derived from paired t-test). WT and mutant SHIP1 30-UTRs as well as
WT and mutant miR-155 are illustrated.reduction in miR-155 expression in all three cell lines, but did
not occur in the GC-DLBCL cell line SUDHL-4 (Fig 3A). Similar
results were obtained when infliximab (Remicade1), a
neutralizing humanized monoclonal antibody against TNFa
was used (not shown). Importantly, reduced miR-155 levels
were accompanied by a concomitant increase in SHIP1 protein
levels in the non-GC-DLBCL cells (Fig 3B).
The biological significance of these observations is evidenced
by the finding that eternacept imposes significant antiprolifera-
tive effects upon the three non-GC-DLBCL cell lines, but did not
produce any growth modulation in the GC-DLBCL cells, or in
Daudi Burkitt lymphoma (Fig 3C).
Our results thus far demonstrated that in non-GC-DLBCL,
elevated levels of miR-155, and consequent abrogation of SHIP1
expression, are mediated through autocrine stimulation of cells
by TNFa, a proinflammatory cytokine whose serum levels are
known to be elevated in DLBCL patients (Pedersen et al, 2005).
To explore the potential efficacy of anti-TNFa regimen as a
treatment for non-GC-DLBCL patients, we employed xenograft
models in which non-obese diabetic/severe combined immu-
nodeficiency (Nod/SCID) mice were subcutaneously inoculatedwww.embomolmed.org EMBO Mol Med 1, 288–295with non-GC-DLBCL Toledo cells. Upon establishment of
palpable tumours, the animals received either 100mg eternacept
or solvent intravenously every three days, and tumour size was
measured after 2, 4 or 6 days. As shown in Fig 4A, eternacept
treatment resulted in a slight, but detectable inhibition in
tumour growth at day 4, and produced a substantial reduction in
tumour burden after 6 days. In concurrence, the analysis of the
excised xenograft tumours revealed increased SHIP1 protein
levels in tumours from eternacept-treated mice compared to
tumours isolated from animals that received phosphate buffered
saline (PBS) (Fig 4B).DISCUSSION
Soon after the discovery of the first mammalian miR some 12
years ago, it became evident that this class of molecules plays a
critical role in global gene regulation, and a likely impact on
cellular survival and death pathways. It is not surprising that
tremendous strides have been made in defining miRNAs
expression profile in human cancers. High throughput analyses, 2009 EMBO Molecular Medicine 291
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Figure 3. Autocrine stimulation of non-GC DLBCL by TNFa. Non-GC-DLBCL cell lines OCILY-3, OCILY-10, Toledo and the GC-DLBCL cell line SUDHL-4 and the
Burkitt lymphoma Daudi were treated with 100 ng/ml eternacept as indicated.
A. miR-155 expression levels were determined by qPCR and normalized to U6 RNA (mean SD; n¼3);
B. Cells were harvested after 72 h, and SHIP1 protein expression was determined by Western blot analysis;
C. Cell proliferation was determined in triplicate cultures 24, 48 and 72h after addition of eternacept (mean SD of at least three independent experiments).
292utilizing various analytical methods demonstrated that miR
expression was commonly dysregulated in a multitude of
human cancers (Calin & Croce, 2006; Lu et al, 2005; Roldo et al,
2006). miR expression profiling has shown promise in defining
malignant status in retrospective studies. It has even been
suggested that microRNA expression profiling can distinguish
cancers according to diagnosis and developmental stage of the
tumour to a greater degree of accuracy than traditional gene
expression analysis.
More than 50% of annotated human miRs genes are located
in fragile chromosomal regions that are susceptible to
amplification, deletion or translocation during the course of
tumour development (Calin et al, 2004). Moreover, recent 2009 EMBO Molecular Medicineevidence indicates that some miRs function either as oncogenes
or tumour suppressors (Esquela-Kerscher & Slack, 2006; He
et al, 2005; Johnson et al, 2005). The first study documenting
abnormalities in miR expression in tumour samples focused on
CLL. Deletion of chromosome 13q14 is the most frequent
chromosomal abnormality in this disorder. Croce and cow-
orkers demonstrated that tumour suppressor activity is likely
provided by two miRNAs, miR-15a and miR-16-1 (Calin et al,
2002). Cimmino et al identified a conserved site for miR-15a and
miR-16-1 in the 30-UTR of the bcl-2 mRNA, which encodes the
anti-apoptotic protein Bcl-2 (Cimmino et al, 2005).
miR-155 was the first onco-miR described, whose expression
in B cells alone is sufficient to trigger malignant transformation,Figure 4. Anti-TNFa regimen inhibits DLBCL
growth in vivo.
A. Sub-lethally irradiated (4Gy) NOD/SCID
mice were injected subcutaneously with
107 non-GC-DLBCL cells (Toledo). Upon
establishment of palpable tumours, mice
were injected every three days with 100mg
eternacept i.v., and tumour size was
measured every second day with callipers
(n¼8/group; p< 0.03; p< 0.01).
B. Xenograft tumours were excised from four
mice in each group and lysates were
analysed by Western blot using SHIP1 and
GAPDH antibodies.
EMBO Mol Med 1, 288–295 www.embomolmed.org
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The paper explained
PROBLEM:
Diffuse large B-cell lymphoma (DLBCL) is clinically,
morphologically and genetically a heterogeneous group of
lymphomas involving malignant proliferation of large lymphoid
B cells. DLBCL accounts for approximately 40% of adult
non-Hodgkin lymphomas (NHL). Two prognostically different
subgroups have been identified, with distinct gene expression
profiles characteristic of either normal germinal centre (GC) B
cells, or activatedmemory B cells with the GC B cell-like subgroup
being correlated with a significantly better prognosis. Recent
work has revealed unique miR signatures in each sub-group, but
the relation of these to tumour growth and malignancy and their
value as prognostic indicators has not been fully clarified.
RESULTS:
The authors identify the inositol phosphatase SHIP1 as a
bonafide target of the oncogenic miR-155. They demonstrate
that DLBCL cells display elevated levels of miR-155 and
consequently diminished expression of SHIP1. They establish
that both features are the result of autocrine stimulation by the
pro-inflammatory cytokine TNF and go on to show that an
anti-TNF regimen involving treatment with eternacept or
infliximab is sufficient to reduce miR-155 levels and restore
SHIP1 expression. These changes are accompanied by a reduction
in cell proliferation and a substantial decrease in tumour burden
in DLBCL xenografts.
IMPACT:
These findings strongly support the concept that
cytokine-regulated miRs can function as a crucial link between
inflammation and cancer, and illustrate the feasibility of
anti-TNFa therapy as a novel and immediately accessible
(co)treatment for DLBCL.albeit no oncogenetically relevant target had been identified.
Under physiological conditions, miR-155 plays an important
role in the formation of GCs through the regulation of cytokine
production (Thai et al, 2007). miR-155-deficiency was found to
be associated with decreased TNFa production, a cytokine
required for GC formation (Endres et al, 1999), whereas forced
expression of miR-155 leads to elevated TNFa levels (Tili et al,
2007). As miR-155 is a TNFa-inducible transcript, these findings
taken together suggest the possibility of a positive amplification
loop. Strikingly, aberrant miR-155 expression in non-GC-DLBCL
appears to be a consequence of an autocrine stimulation by
TNFa rather than the result of a chromosomal translocation, as
miR-155 and SHIP1 levels can be reduced or increased,
respectively, through the administration of neutralizing anti-
TNFa antibodies or soluble TNFa receptor. It is apparent that
miR-155 is not the only target gene upregulated by TNFa, nor is
it likely that SHIP1 is the sole target of miR-155. However, there
is no doubt about the oncogenic properties of miR-155, or
the tumour-suppressive effects of the inositol-phosphatases
SHIP1 and PTEN. Extensive additional studies employing
transgenic re-introduction of SHIP1 into miR-155-transgenic
mice will be required to address the importance of
SHIP suppression in the oncogenic transformation elicited by
miR-155. Our current results nevertheless not only clearly
illustrate that the expression levels of SHIP1 and miR-155
are valuable prognostic indicators in DLBCL, but also
strongly support the concept that inflammatory miRs
contribute to the development or progression of cancer. Most
importantly, our studies demonstrate the feasibility of anti-
TNFa therapy as a novel and immediately accessible (co)treat-
ment for DLBCL.www.embomolmed.org EMBO Mol Med 1, 288–295MATERIALS AND METHODS
Cell culture
OCILY-3, OLILY-10 and Toledo cells were maintained in complete
Iscove’s DMEM (Dulbecco’s modied Eagle’s medium)þ20% human
serumþ100mg/ml penicillin/streptomycinþ2mM L-glutamine (In-
vitrogen, Carlsbad, CA). SUDHL-4 and Daudi cells were maintained
in complete Roswell Park Memorial Institute (RPMI) mediumþ10%
foetal calf serum (FCS)þ100mg/ml penicillin/ streptomycinþ2mM
L-glutamine. Where indicated, cells were treated with 400nM c-Jun
N-terminal kinase (JNK) Inhibitor II (Calbiochem, San Diego, CA),
and/or 20 ng/ml of human TNFa (Peprotech Inc., Rocky Hill, NJ).
Cell proliferation was determined using a Beckman Coulter Counter.
Patient samples
Sections of frozen biopsies were stained for CD10 (clone: 56C6,
Novocastra), Bcl-6 (clone: PGBGp, DAKO) and multiple myeloma
oncogene 1 (MUM1) (MUM1p, DAKO) in a Techmate 500 Immunos-
tainer using DAKO Envision K5007 as a secondary antibody. CD10
positive or Bcl-6 positive, MUM1 negative samples were classified as
GCB-DLBCLas described by Hans et al (Hans et al, 2004). For LCD,
lymph node sections were stained with haematoxylin and eosin (H&E)
staining kit (Molecular Machines Industries, Glattbrugg, Switzerland),
and lymphoma cells (1,000 cells/patient specimen) were isolated
using the MMI CellCut (MMI). All human material was handled in full
compliance with NIH guidelines and IRB approval.
Luciferase Assays
The putative target site of the miR-155 seed sequence in the
30-UTR of hSHIP1 (WT; 50-AGCTTGGGCTTCTTAATGCTTTCACCCCTCA-30
and 50-CTAGTGAGGGGTGAAAGCATTAAGAAGCCCA-30) or a mutated
variant (Mut; 50-AGCTTGGGCTTCTGGGTGCTTTCACCCCTCA-30 and 50- 2009 EMBO Molecular Medicine 293
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294CTAGTGAGGGGTGAAAGCACCCAGAAGCCCA-30) were cloned into the
pmiReport firefly-luciferase vector (Applied Biosystems, Foster City,
CA). 293 T cells at 50% confluency were transfected in triplicate using
lipofectamin with the pmiReport luciferase vectors and either miR-
CTL#1, miR-155 or a miR-155 variant (50-GGGAUAGUGCUAAUC-
GUGGGU; all from Dharmacon, Lafayette, CO) complementary to the
altered putative target site introduced in the pmiReport luciferase
vector. Renilla luciferase under the control of a cytomegalovirus (CMV)
promoter was co-transfected to serve as internal reference. After 24 h,
cells were washed in PBS and luciferase activities were measured
using Promega’s Dual Luciferase Assay System.
Transfection of miRs
OptiMem (Invitrogen) and Mirus transfection reagent (Mirus Bio/
Fisher Scientific) were combined according to the manufacturer’s
instructions, and miR mimics or anti-miRs (mimics from Dharmacon;
anti-miRs from Applied Biosystems) were introduced prior to addition
of the transfection mix to the cells.
RNA isolation and quantitative polymerase chain reaction
(qPCR)
RNA was extracted using TriZol following the manufacturer’s protocol
(Invitrogen), and miR kits (RT and TaqMan q-PCR primers, Applied
Biosystems) were used for qPCR analysis of miR-155, U6 and U43
according to the manufacturer’s instructions. qPCR analysis of SHIP1
and GAPDH mRNA was performed using specific primers for SHIP1
(SABiosciences, Frederick, MD) and GAPDH (Dharmacon). Relative
expression was calculated using the comparative threshold cycle (Ct)
method.
Western blot analysis
Cell lysates were subject to Western blot analysis using rabbit
monoclonal antibodies against SHIP1, SHIP2 or GAPDH (Cell Signaling
Tech, Danbars, MA), and blots were developed using ECL (GE
Healthcare).
Xenografts
Nod/SCID mice were subcutaneously inoculated with 107 Toledo cells.
Upon establishment of palpable tumours, the animals received either
100mg eternacept or an equal volume of solvent intravenously every
three days. Tumour size was measured after 2, 4 and 6 days. Tumours
were excised at day 6, lysed and analysed by Western blot for SHIP1
expression. All experiments were approved by UCSD Institutional
Animal Care Committee.Author contributions
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